Loading…
Customceutical Compounding, a drug compounding company, received an FDA Warning Letter on August 25, 2020. Based on the limited metadata available, the specific violations cannot be determined as the subject line is not provided. The letter was issued under FDA's drug regulatory authority, though the specific issuing office is not identified in the available metadata. To understand the full scope and nature of the compliance issues cited, the complete letter text would be needed.